Andrew Moreno

DocwireNews

Encouraging new data show lintuzumab-Ac-225 (Actimab-A) to be a promising treatment backbone for relapsed or refractory acute myeloid leukemia (AML), Actinium Pharmaceuticals, Inc., reports in a press release. These data on combinations that incorporate this new radiotherapy were presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, in April 2025.1Lintuzumab-Ac-225 is a CD33-targeting radiotherapy that hones a powerful alpha-emitter radioisotope, actinium-225, for antileukemic effect. It is Actinium Pharmaceuticals&rsquo; lead product candidate and in development for management of AML, myelodysplastic syndromes (MDS), and other myeloid malignancies.1Regarding the radiotherapy&rsquo;s performance in past AML clinical trials, Actinium Pharmaceuticals chair and chief executive officer Sandesh Seth commented in a press release that &ldquo;Actimab-A has demonstrated potent single agent activity, synergy with other therapeutic modalities and efficacy in patients with high-risk features such as a TP53 mutation.&rdquo;1The data presented at the AACR Annual Meeting were from preclinical models in which lintuzumab-Ac-225 was combined with standard-of-care targeted therapies for relapsed and refractory AML: azacitidine, the FLT3 inhibitors gilteritinib and quizartinib, and the KMT2A inhibitors revumenib and ziftomenib. The results showed a significant antileukemic effect of these combinations against AML cell lines that featured FLT3, KMT2A, NPM1, and TP53 mutations.2&ldquo;The data presented at AACR further support Actimab-A&rsquo;s mutation agnostic mechanism of action across several of the most commonly expressed mutations and synergy with the targeted therapies approved for patients with these mutations,&rdquo; Seth elaborated in the press release.1Clinical trial work on use of lintuzumab-Ac-225 within polytherapy approaches for AML continues, including in a phase 2/3 trial in which the radiotherapy will be combined with the CLAG-M (cladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and dose-escalated mitoxantrone) chemotherapy regimen for relapsed or refractory disease. Another trial, to take place under a Cooperative Research and Development Agreement between Actinium Pharmaceuticals and the National Cancer Institute, will evaluate triplet therapy consisting of lintuzumab-Ac-225 plus venetoclax and the novel oral hypomethylating agent ASTX-727 for frontline AML management. Prior clinical results of treatment with lintuzumab-Ac-225 for high-risk relapsed and refractory disease have also been positive, including findings in patients with prior venetoclax treatment or bone marrow transplant.1Reference<ol>
<li>Actinium Pharmaceuticals, Inc. Accessed May 8, 2025. <a href="https://ir.actiniumpharma.com/press-releases/detail/501">https://ir.actiniumpharma.com/press-releases/detail/501</a></li>
<li>Chin AS, et al. American Association for Cancer Research Annual Meeting 2025. Abstract nr 594. <a href="https://doi.org/10.1158/1538-7445.AM2025-594">https://doi.org/10.1158/1538-7445.AM2025-594</a></li>
</ol>

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Promising Data Presented on Novel Radiotherapy for AML, MDS, Myeloid Malignancies

Preclinical models show significant efficacy in combos against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe